Recent Updates
Recently added Catalysts
PYPD

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the Midwest Surgical Association 2022 Annual Meeting

Key Takeaway: Efficacy Data of D-PLEX100 in the Prevention of Post-Abdominal Surgery Incisional Infection in High-Risk Patients will be Presented During a Podium Presentation PETACH TIKVA, Israel, July 25, 2022 (GLOBE NEWSWIRE) --  PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a l

Full Press Release Details

Efficacy Data of D-PLEX100 in the Prevention of Post-Abdominal Surgery Incisional Infection in High-Risk Patients will be Presented During a Podium Presentation
PETACH TIKVA, Israel, July 25, 2022 (GLOBE NEWSWIRE) --  PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Phase 2 clinical data for D-PLEX100 will be highlighted in a podium presentation at the Midwest Surgical Association 2022 Annual Meeting being held on August 7-9, 2022, at the Grand Hotel in Mackinac Island, Michigan.
Midwest Surgical Association 2022 Annual Meeting:
Presentation Title: Reduction in Surgical Site Infections by Localized Administration with D-PLEX 100 in Patients with Multiple Risk Factors Undergoing Colorectal Surgery
Presenter: Anthony J. Senagore, M.D., Senior Medical Director of PolyPid
Date/Time: Monday, August 8, 2022, Scientific Session I, 8:15 a.m. – 8:30 a.m.
The presentation will be available on http://www.polypid.com/ following its conclusion.
Last updated: Jul 25, 2022